NMTR earnings

Positive final results from the vurolenatide Phase 2 VIBRANT study in short bowel syndrome (SBS) reaffirmed the efficacy and safety of vurolenatide and determined the Phase 3 dose and regimenClinical plans and activities are underway including site and patient recruitment to facilitate Phase 3 study initiation upon protocol finalization with FDA this quarterRALEIGH, NC / ACCESSWIRE / November 8, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the third quarter ended Septembe

Positive preliminary results from Phase 2 VIBRANT study of vurolenatide in short bowel syndrome announcedVurolenatide End-of-Phase 2 meeting with FDA on track for 3QCash balance as of June 30, 2022 of $29.5 million; additional $20 million from previously announced July debt financing extends cash runway into 4Q 2023RALEIGH, NC / ACCESSWIRE / August 15, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the second quarter ended June 30, 2022.John Temperato, President & Chief Exe

On track to report Phase 2 data for vurolenatide for short bowel syndrome and Phase 3 interim analysis for celiac disease in JuneCash balance as of March 31, 2022, of $37.2 million is expected to fund ongoing clinical programs and business operations into Q2 2023RALEIGH, NC / ACCESSWIRE / May 16, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the first quarter ended March 31, 2022.John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, commented: "This is

RALEIGH, NC / ACCESSWIRE / March 23, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the fourth quarter and full year ended December 31, 2021.John Temperato, President & CEO of 9 Meters Biopharma, commented: "2021 was an exceptionally productive year for 9 Meters as we significantly advanced our pipeline, particularly our lead assets vurolenatide for short bowel syndrome (SBS) and larazotide for celiac disease. We look forward to meaningful data readouts in the second quarte

- Phase 2 vurolenatide VIBRANT study enrollment anticipated to be completed before year-end; topline results for short bowel syndrome expected in Q1 2022 -- Larazotide Phase 3 for celiac disease interim analysis expected in Q2 2022 -- Appointed Samantha Ventimiglia of Vertex to the Board of Directors -- Quarter ending cash of $53.6 million is expected to fund operations into 2023 -RALEIGH, NC / ACCESSWIRE / November 15, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today provided a business update and reported financial results for the t

Conference Call Scheduled for August 12, 2021 RALEIGH, NC / ACCESSWIRE / August 5, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), today announced that the Executive Management team will participate in the Biopharma Spotlight Series: Innovation in GI Conference Call hosted by Gary Nachman and BMO Capital Markets. Please see additional details below:Biopharma Spotlight Series: Innovation in GI Conference Call Date: Thursday, August 12th, 2021Time: 11:35 am Eastern TimeTitle: DEEP DIVE ON SHORT BOWEL SYNDROME Webcast link: https://bmo.qumucloud.com/view/2021-biopharma-9metersManagement: John Temperato, President & CEO Patrick Griffin , Chief Medical Officer* a replay will be available following

FDA Type C meeting communications support plans to initiate Phase 2 in Q2 with NM-002 for short bowel syndrome (SBS) using Total Stool Output (TSO) as a primary efficacy outcome measure  Announced positive topline data in December for NM-002, a proprietary long-acting GLP-1, in a Phase 1b/2a trial for SBS  Company's R&D day on March 23rd to include additional Phase 1b/2a study data on parenteral support, pharmacokinetics and quality of life  Phase 3 interim analysis and topline data for larazotide in celiac disease now anticipated in 2022 due to COVID-19 impact on patient enrollment  Raised over $58 million from prominent institutional healthcare investors in 2020  Research & Develop